Author

J. Herriott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:rat· 1

Frequent Co-Authors

A. Owen· 4 shared H. Pertinez· 4 shared J. Sharp· 4 shared M. Neary· 4 shared P. Curley· 4 shared U. Arshad· 4 shared A. Valentijn· 3 shared E. Kijak· 3 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

A. Owen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

H. Pertinez, A. Kaushik, P. Curley, U. Arshad, E. El-Khateeb, S.-Y. Li, R. Tasneen, J. Sharp, E. Kijak, J. Herriott, M. Neary, M. Noe, C. Flexner, E. Nuermberger, A. Owen, N. C. Ammerman

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

bioRxiv · Mar 3, 2024 · PreprintPharmacology & Toxicology

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.

H. J. Box, S. H. Pennington, E. Kijack, L. Tatham, C. H. Caygill, R. C. Lopeman, L. N. Jeffreys, J. Herriott, J. Sharp, M. Neary, A. Valentijn, H. Pertinez, P. Curley, U. Arshad, R. K. Rajoli, , A. Owen

This paper investigates probenecid's antiviral activity against SARS-CoV-2 in Vero E6 cells and Syrian golden hamsters, finding no significant inhibition of viral replication or cytopathic effects.

bioRxiv · Mar 3, 2022 · PreprintPharmacology & Toxicology

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV 2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case

L. Tatham, A. Kipar, J. Sharp, E. Kijak, J. Herriott, M. Neary, H. Box, E. Gallardo Toledo, A. Valentijn, H. Cox, H. Pertinez, P. Curley, U. Arshad, R. K. Rajoli, S. Rannard, , A. Owen

This study evaluates Ronapreve's efficacy against SARS-CoV-2 Delta and Omicron variants in mice, showing reduced viral burden and altered pulmonary response for Delta but not Omicron.

bioRxiv · Jan 23, 2022Microbiology

Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters

M. Neary, H. Box, J. Sharp, L. Tatham, P. Curley, J. Herriott, E. Kijak, U. Arshad, J. J. Hobson, R. K. Rajoli, H. Pertinez, A. Valentijn, K. Dhaliwal, F. McCaughan, S. P. Rannard, , A. Owen

This study evaluates intranasal nafamostat and camostat for preventing SARS-CoV-2 infection in Syrian golden hamsters, finding nafamostat effective in keeping viral RNA undetectable for 7 days.

bioRxiv · Jul 8, 2021 · PreprintPharmacology & Toxicology